---
schema_version: "secwatch.filing_event.v1"
accession: "0001649094-26-000021"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2026-06-16T20:12:10+00:00"
generated_at: "2026-06-16T20:13:22.938695+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte shareholders re-elect all three Class III directors, ratify Deloitte, approve say-on-pay

## Summary
- Three Class III directors re-elected: Brandicourt (116.4M for), Gilbert (114.7M for), Pickering (132.1M for); 4.4M broker non-votes.
- Ratification of Deloitte as auditor for FY2026 passed with 137.2M for, 137,589 against, 862 abstain.
- Non-binding advisory vote on named executive officer compensation approved with 130.0M for, 2.8M against, 247,195 abstain, 4.4M broker non-votes.
- All proposals passed as recommended by the board; no material strategic or financial changes disclosed.

## SEC filing metadata
- accession: 0001649094-26-000021
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2026-06-16T20:12:10+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000021/0001649094-26-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000021/pcvx-20260615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001649094-26-000021
- JSON: https://secwatch.observer/filing/0001649094-26-000021.json
- Plain text: https://secwatch.observer/filing/0001649094-26-000021.txt

## Key facts
- Shareholder Votes
  Vaxcyte, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-15 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-15
  source text: 2. The ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The appointment was ratified by the votes indicated: For Against Abstain 137,230,032 137,589 862
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000021/0001649094-26-000021-index.htm
- Shareholder Votes
  Vaxcyte, Inc. shareholders approved Election of three Class III directors to serve until the Company's 2029 Annual Meeting of Stockholders at the 2026-06-15 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-15
  source text: 1. The election of three nominees to serve as Class III directors until the Company’s 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director’s death, resignation or removal. The following three Class III directors were re-elected by the votes indicated: For Withheld Broker Non-Votes Olivier Brandicourt, M.D. 116,370,183 16,643,897 4,354,403 Halley Gilbert, J.D. 114,704,274 18,309,806 4,354,403 Grant Pickering, M.B.A. 132,112,840 901,240 4,354,403
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000021/0001649094-26-000021-index.htm
- Shareholder Votes
  Vaxcyte, Inc. shareholders approved Approval, on a non-binding, advisory basis of the compensation of the Company's named executive officers at the 2026-06-15 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-15
  source text: 3. The approval, on a non-binding, advisory basis of the compensation of the Company's named executive officers. The approval of the non-binding resolution on named executive officer compensation was approved by the votes indicated: For Against Abstain Broker Non-Votes 130,011,017 2,755,868 247,195 4,354,403
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000021/0001649094-26-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.